Skip to main content
main-content

The independent medical news service

24-06-2022 | Oncology | News | Article

Focal ultrasound may offer intermediate-risk prostate cancer alternative to radiation, surgery

Magnetic resonance imaging-guided focal ultrasound therapy is a feasible treatment for grade group 2–3 prostate cancer, indicate phase 2b trial findings published in The Lancet Oncology.

22-06-2022 | Oncology | Highlight | Article

Enzalutamide during active surveillance may delay prostate cancer progression

The ENACT trial has demonstrated a significantly reduced risk for progression with the use of enzalutamide in men with low- or intermediate-risk localized prostate cancer undergoing active surveillance.

07-06-2022 | Oncology | News | Article

ENZAMET update confirms benefits of add-on enzalutamide

An updated analysis of the ENZAMET trial confirms earlier findings that adding enzalutamide to testosterone suppression provides statistically and clinically meaningful survival improvements in metastatic hormone-sensitive prostate cancer.

26-05-2022 | Oncology | News | Article

Large study finds no increased risk for prostate cancer death with 5-ARI use

Use of 5α-reductase inhibitors is not associated with an increased risk for prostate cancer mortality, and long-term use may indeed reduce the risk, a Swedish population-based study has found.

19-05-2022 | Oncology | News | Article

ASCO releases guideline on lifestyle changes during cancer treatment

Find out more about the recommendations on exercise, diet, and weight management here

10-05-2022 | Oncology | News | Article

Prostate cancer death linked to increases in BMI, waist size

A meta-analysis has identified a significantly elevated risk for prostate cancer-specific mortality with increases in BMI, waist circumference, and waist-to-hip ratio.